Table 1.
Baseline characteristics and outcomes of the study population (LYMPHONIE study, 2018–2020).
| Study group | p | ||
|---|---|---|---|
| Non-COVID-19 | COVID-19 | ||
| N = 36 | N = 27 | ||
| Demographics | |||
| Age (years), median (IQR) | 67.5 (63–76.5) | 64 (57–71) | 0.06 |
| Male sex, n (%) | 29 (81%) | 17 (63%) | 0.12 |
| Body mass index (kg/m2), median (IQR) | 27 (25–33) | 31 (27–34) | 0.30 |
| Chronic comorbidities | |||
| Cardiovascular disease, n (%) | 12 (33%) | 5 (19%) | 0.25 |
| Pulmonary disease, n (%) | 12 (33%) | 5 (19%) 28 | 0.25 |
| Chronic renal disease, n (%) | 2 (6%) | 1 (4%) | 0.73 |
| Cerebrovascular disease, n (%) | 5 (14%) | 3 (11%) | 0.74 |
| Diabetes mellitus, n (%) | 10 (28%) | 2 (7%) | 0.28 |
| Charlson score, mean±SD | 1.5 ± 2.0 | 0.9 ± 0.9 | 0.12 |
| Severity at hospital admission | |||
| Septic shock, n (%) | 11 (31%) | 0 | 0.0015 |
| ARDS, n (%) | 23 (64%) | 25 (93%) | 0.015 |
| Pneumonia Severity Index, mean±SD | 117.8 ± 38.6 | 94.2 ± 27.1 | 0.006 |
| SOFA score, mean±SD | 7.2 ± 3.6 | 6.7 ± 2.0 | 0.52 |
| Biological findings at admission | |||
| ASAT (IU/l), mean±SD | 86.3 ± 92.4 | 86.2 ± 54.6 | 0.99 |
| Serum creatinine (μmol/l), mean±SD | 132.9 ± 93.3 | 90.2 ± 40.7 | 0.02 |
| PaO2:FiO2 (mm Hg), mean±SD | 123.7 ± 54.9 | 136.2 ± 49.8 | 0.35 |
| Lactate level (mmol/l), mean±SD | 2.6 ± 1.9 | 1.7 ± 0.7 | 0.01 |
| Glucose metabolism and adipokines | |||
| Glycemia (mmol/l), mean±SD | 16 ± 8 | 12 ± 6 | 0.024 |
| Insulin (mU/l), mean±SD | 15 ± 25 | 13 ± 13 | 0.63 |
| Leptin (ng/ml), mean±SD | 18.5 ± 27.5 | 15.0 ± 19.1 | 0.58 |
| Adiponectin (ng/ml), mean±SD | 5338 ± 4024 | 4090 ± 2745 | 0.18 |
| Adiponectin/Leptin ratio | 1.5 ± 2.1 | 1.2 ± 2.9 | 0.61 |
| Outcomes at 30 days | |||
| Median days of mechanical ventilation (IQR) | 4 (0–15) | 15 (7–22) | 0.0049 |
| Median hospital length of stay (days) (IQR) | 21 (13–30) | 29 (20–30) | 0.087 |
| 30-day mortality, n (%) | 2 (6%) | 1 (4%) | 1 |